Predictably Non-Bayesian: Quantifying salience effects in physician learning about drug quality

Marketing Science

Volumn 30, Issue 2, 2011, Pages 305-320

  Camacho, Nuno ^a   Donkers, Bas ^a   Stremersch, Stefan ^a,b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b IESE BUSINESS SCHOOL   (Spain)

Author keywords

Behavioral modeling; Consumer learning; Medical decision making; New drug adoption; Physician learning; Quasi Bayesian learning models

Indexed keywords

EID: 79955057469     PISSN: 07322399     EISSN: 1526548X     Source Type: Journal    
DOI: 10.1287/mksc.1100.0624     Document Type: Article

References (61)

1. Arkes, H. R. 1991. Costs and benefits of judgment errors: Implications for debiasing. Psych. Bull. 110(3) 486-498.
2. Baumeister, R. F., E. Bratslavsky, C. Finkenauer, K. D. Vohs. 2001. Bad is stronger than good. Rev. General Psych. 5(4) 323-370.
3. Bornstein, B. H., A. C. Emler, G. B. Chapman. 1999. Rationality in medical treatment decisions: Is there a sunk-cost effect? Soc. Sci. Med. 49(2) 215-222.
4. Boulding, W., A. Kalra, R. Staelin. 1999. The quality double whammy. Marketing Sci. 18(4) 463-484.
5. Bradley, C. P. 2005. Commentary: Can we avoid bias? British Medical J. 330(April) 784.
6. Brewin, T. 1994. Primum non nocere? Lancet 344(8935) 1487-1488.
7. Cacioppo, J. T., W. L. Gardner. 1999. Emotion. Annual Rev. Psych. 50(February) 191-214.
8. Calverley, P. M., J. A. Anderson, B. Celli, G. T. Ferguson, C. Jenkins, P. W. Jones, J. C. Yates, J. Vestbo. 2007. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New Engl. J. Med. 356(8) 775-789.
9. Camerer, C. F., G. Loewenstein. 2004. Behavioral Economics: Past, Present, Future. Princeton University Press, Princeton, NJ.
10. Casella, G., E. I. George. 1992. Explaining the Gibbs sampler. Amer. Statistician 46(3) 167-174.
11. Chan, T., C. Narasimhan, Y. Xie. 2010. An empirical model of physician learning on treatment effectiveness and side-effects. Working paper, Washington University in St. Louis, St. Louis.
12. Chib, S., E. Greenberg. 1995. Understanding the Metropolis- Hastings algorithm. Amer. Statistician 49(4) 327-335.
13. Ching, A., M. Ishihara. 2010. The effects of detailing on prescribing decisions under quality uncertainty. Quant. Marketing Econom. 8(2) 123-165.
14. Chintagunta, P. K., R. Jiang, G. Z. Jin. 2009. Information, learning, and drug diffusion: The case of Cox-2 inhibitors. Quant. Marketing Econom. 7(4) 399-443.
15. Coscelli, A. 2000. The importance of doctors' and patients' preferences in the prescription decision. J. Indust. Econom. 48(3) 349-369.
16. Coscelli, A., M. Shum. 2004. An empirical model of learning and patient spillovers in new drug entry. J. Econometrics 122(2) 213-246.
17. Crawford, G. S., M. Shum. 2005. Uncertainty and learning in pharmaceutical demand. Econometrica 73(4) 1137-1173.
18. Croskerry, P. 2002. Achieving quality in clinical decision making: Cognitive strategies and detection of bias. Acad. Emergency Med. 9(11) 1184-1204.
19. Croskerry, P. 2003. The importance of cognitive errors in diagnosis and strategies to minimize them. Acad. Med. 78(8) 775-780.
20. Datamonitor. 2008. Forecast insight: Asthma/COPD-Little longterm future for long-acting single-agent inhalers? Report DMHC2439, Datamonitor, London.
21. DeGroot, M. H. 1970. Optimal Statistical Decisions. John Wiley & Sons, Hoboken, NJ.
22. Elstein, A. S., A. Schwartz. 2002. Clinical problem solving and diagnostic decision making: Selective review of the cognitive literature. British Medical J. 324(7339) 729-732.
23. Epstein, L. G. 2006. An axiomatic model of non-Bayesian updating. Rev. Econom. Stud. 73(2) 413-436.
24. Erdem, T., M. P. Keane. 1996. Decision-making under uncertainty: Capturing dynamic brand choice processes in turbulent consumer goods markets. Marketing Sci. 15(1) 1-20.
25. Estrada, C. A., A. M. Isen, M. J. Young. 1997. Positive affect facilitates integration of information and decreases anchoring in reasoning among physicians. Organ. Behav. Human Decision Processes 72(1) 117-135.
26. Fiscella, K., P. Franks, J. Zwanziger, C. Mooney, M. Sorbero, G. C. Williams. 2000. Risk aversion and costs: A comparison of family physicians and general internists. J. Family Practice 49(1) 12-17.
27. Geweke, J. 1992. Evaluating the accuracy of sampling-based approaches to the calculation of posterior moments. J. M. Bernardo, J. O. Berger, A. P. Dawid, A. F. M. Smith, eds. Bayesian Statistics, Vol. 4. Oxford University Press, Oxford, UK, 169-193.
28. Global Initiative for Asthma (GINA). 2008. Global strategy for asthma management and prevention. Report, GINA, http://www.ginasthma.com/Guidelineitem.asp??/1=2&/2=1&intId=60.
29. Goldenberg, J., B. Libai, S. Moldovan, E. Muller. 2007. The NPV of bad news. Internat. J. Res. Marketing 24(3) 186-200.
30. Griffin, D., A. Tversky. 1992. The weighing of evidence and the determinants of confidence. Cognitive Psych. 24(3) 411-435.
31. Hall, K.H. 2002. Reviewing intuitive decision-making and uncertainty: The implications for medical education. Medical Ed. 36(3) 216-224.
32. Häubl, G., B. G. C. Dellaert, B. Donkers. 2010. Tunnel vision: Local behavioral influences on consumer decisions in product search. Marketing Sci. 29(3) 438-455.
33. Ho, T. H., N. Lim, C. F. Camerer. 2006. Modeling the psychology of consumer and firm behavior with behavioral economics. J. Marketing Res. 43(3) 307-331.
34. Kass, R. E., A. E. Raftery. 1995. Bayes factors. J. Amer. Statist. Assoc. 90(430) 773-795.
35. Klein, J. G. 2005. Five pitfalls in decisions about diagnosis and prescribing. British Medical J. 330(7494) 781-783.
36. Marks, N. A., P. W. Ind. 2005. Novel therapies in asthma: Long-acting _2-agonists/inhaled corticosteroids. P. G. Gibson, M. Abramson, U. Costabel, M. Hensley, J. Volmink, R. Wood-Baker, eds. Evidence-Based Respiratory Medicine. Blackwell Publishing, Malden, MA, 217-230.
37. McCulloch, R., P. E. Rossi. 1994. An exact likelihood analysis of the multinomial probit model. J. Econometrics 64(1-2) 207-240.
38. Medin, D. L., M. W. Altom, S. M. Edelson, D. Freko. 1982. Correlated symptoms and simulated medical classification. J. Experiment. Psych.: Learn., Memory, Cognition 8(1) 37-50.
39. Mehta, N., X. J. Chen, O. Narasimhan. 2008. Informing, transforming, and persuading: Disentangling the multiple effects of advertising on brand choice decisions. Marketing Sci. 27(3) 334-355.
40. Mehta, N., S. Rajiv, K. Srinivasan. 2004. Role of forgetting in memory-based choice decisions: A structural model. Quant. Marketing Econom. 2(2) 107-140.
41. Mizerski, R. W. 1982. An attribution explanation of the disproportionate influence of unfavorable information. J. Consumer Res. 9(3) 301-310.
42. Narasimhan, C., C. He, E. T. Anderson, L. Brenner, P. Desai, D. Kuksov, P. Messinger et al. 2005. Incorporating behavioral anomalies in strategic models. Marketing Lett. 16(3/4) 361-373.
43. Narayanan, S., P. Manchanda. 2009. Heterogeneous learning and the targeting of marketing communication for new products. Marketing Sci. 28(3) 424-441.
44. Narayanan, S., P. Manchanda, P. K. Chintagunta. 2005. Temporal differences in the role of marketing communication in new product categories. J. Marketing Res. 42(3) 278-290.
45. Nisbett, R. E., D. H. Krantzm C. Jepson, Z. Kunda. 1983. The use of statistical heuristics in everyday inductive reasoning. Psych. Rev. 90(4) 339-363.
46. Oliver, R. L. 1993. Cognitive, affective, and attribute bases of the satisfaction response. J. Consumer Res. 20(3) 418-430.
47. Poses, R. M., M. Anthony. 1991. Availability, wishful thinking, and physicians' diagnostic judgments for patients with suspected bacteremia. Medical Decision Making 11(3) 159-168.
48. Rabin, M., J. L. Schrag. 1999. First impressions matter: A model of confirmatory bias. Quart. J. Econom. 114(1) 37-82.
49. Raftery, A. E., S. M. Lewis. 1992. How many iterations in the Gibbs sampler? J. M. Bernardo, J. O. Berger, A. P. Dawid, A. F. M. Smith, eds. Bayesian Statistics, Vol. 4. Oxford University Press, Oxford, UK, 763-773.
50. Redelmeier, D. A. 2005. The cognitive psychology of missed diagnoses. Ann. Internal Med. 142(2) 115-120.
51. Roberts, J. H., G. L. Urban. 1988. Modeling multiattribute utility, risk, and belief dynamics for new consumer durable brand choice. Management Sci. 34(2) 167-185.
52. Rossi, P. E., G. M. Allenby, R. McCulloch. 2005. Bayesian Statistics and Marketing. John Wiley & Sons, West Sussex, UK.
53. Rozin, P., E. B. Royzman. 2001. Negativity bias, negativity dominance, and contagion. Personality Soc. Psych. Rev. 5(4) 296-320.
54. Stremersch, S. 2008. Health and marketing: The emergence of a new field of research. Internat. J. Res. Marketing 25(4) 229-233.
55. Stremersch, S., W. Van Dyck. 2009. Marketing of the life sciences: A new framework and research agenda for a nascent field. J. Marketing 73(July) 4-30.
56. Swait, J., J. Louviere. 1993. The role of the scale parameter in the estimation and comparison of multinomial logit models. J. Marketing Res. 30(3) 305-314.
57. Tanner, M. A., W. H. Wong. 1987. The calculation of posterior distributions by data augmentation. J. Amer. Statist. Assoc. 82(398) 528-540.
58. Taylor, S. E. 1991. Asymmetrical effects of positive and negative events: The mobilization-minimization hypothesis. Psych. Bull. 110(1) 67-85.
59. Tversky, A., D. Kahneman. 1974. Judgment under uncertainty: Heuristics and biases. Science 185(4157) 1124-1131.
60. Venkataraman, S., S. Stremersch. 2007. The debate on influencing doctor's decisions: Are drug characteristics the missing link? Management Sci. 53(11) 1688-1701.
61. Vlug, A. E., J. van der Lei, B. M. Mosseveld, M. A. van Wijk, P. D. van der Linden, M. C. Sturkenboom, J. H. van Bemmel. 1999. Postmarketing surveillance based on electronic patient records: The IPCI project. Methods Inform. Med. 38(4-5) 339-344.